# Alethiomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alethiomics

- Industry: Biotechnology
- Headquarters: Oxford, UK
- Website: www.alethiomics.com
- Total disclosed funding: $6.8M
- Latest round: Seed (Dec 15, 2021)
- Investors on record: 1

## About

Alethiomics Ltd is a biotechnology company focused on developing innovative treatments for blood cancer through advanced biological insights derived from single-cell analysis, aiming to enhance patient care and outcomes.Founded in 2021 and headquartered in Oxford, UK, Alethiomics Ltd is dedicated to advancing the discovery and development of treatments for blood cancer. The company raised EUR 6.000 mn in Seed funding in December 2021 from Oxford Sciences Enterprises, marking a significant step in their growth.Alethiomics specializes in discovering and developing innovative treatments for blood cancer, utilizing advanced biological insights from single-cell analysis. Their core offerings focus on identifying novel biological targets that potentially unveil new treatment pathways, addressing critical unmet medical needs in oncology. Alethiomics serves hospitals, research institutions, and pharmaceutical companies throughout North America and Europe, particularly in regions with a high prevalence of blood cancer.Alethiomics generates revenue through partnerships with healthcare providers and pharmaceutical companies, focusing on collaborative research and development. Revenue is derived from strategic alliances involving long-term agreements for access to the company's proprietary technologies and oncology research expertise. Financial transactions may include milestone payments tied to specific research achievements, forming a structured revenue framework reflecting a B2B model that supports ongoing innovation.With the EUR 6.000 mn raised in Seed funding in December 2021, Alethiomics plans to advance its multi-omics target discovery pipeline in blood cancer. The company is focused on enhancing its product offerings and expanding its reach into new markets, particularly targeting regions where blood cancer is prevalent. This funding will facilitate the development of new products and bolster research initiatives aimed at improving patient outcomes.

## Funding rounds

- Seed, Dec 15, 2021, $6.8M — Oxford Sciences Enterprises

## Investors

- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Seed